InMed Pharmaceuticals is the first company to advance cannabinol (CBN) into clinical trials for therapeutic development. It has begun a Phase 1 clinical trial in healthy volunteers for INM-755 CBN cream, its lead program in epidermolysis bullosa (EB). CBN is also the active pharmaceutical ingredient in InMed’s second program in glaucoma. In this video, InMed CEO Eric A. Adams talks about CBN’s distinct structural properties and its potential in treatments for skin and ocular diseases.
![](https://www.inmedpharma.com/wp-content/uploads/2024/07/InMed_INM-089-Article-Investor-Wire-768x398.png)
Article: InMed Pharmaceuticals Inc.’s (NASDAQ: INM) INM-089, a Promising Treatment for Age-Related Macular Degeneration
In this article, read about the prevalence of age-related macular degeneration and InMed’s promising preclinical studies of INM-089, a small molecule drug candidate in development